Category - Markets

Markets

Stifel starts Reata Pharma at buy

Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22. “Our positive thesis centers on what we see as blockbuster potential for...

February 23, 2017

Markets

Roth downgrades ANI Pharma to neutral

Roth Capital Partners downgraded ANI Pharmaceuticals (NASDAQ:ANIP) to “neutral” from “buy,” pending the company’s 2017 financial guidance. Roth maintained its $69 price target for the stock, which was quoted at $59.53...

February 22, 2017

Markets

Stifel downgrades Argos to hold

Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase...

February 22, 2017

Markets

BTIG downgrades Entellus Medical to neutral

BTIG downgraded Entellus Medical (NASDAQ:ENTL) to “neutral” from “buy,” saying that “something has gone off course” after the company reported Q4 results on Feb. 21. The stock closed at $17.08 yesterday. “For some time...

February 22, 2017

Markets

Stifel starts AnaptysBio at buy

Stifel launched coverage of AnaptysBio (NASDAQ:ANAB) with a “buy” rating and $30 price target. The stock closed at $23.89 on Feb. 17. “AnaptysBio, at its core, is a unique antibody generation company capable of directed...

February 21, 2017

Markets

Leerink starts ObsEva at OP

Leerink initiated coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and a 12-month price target of $21. The stock closed at $13.21 on Feb. 17. ObsEva is a clinical-stage biopharmaceutical company focused...

February 21, 2017

Markets

Mackie ups Medicure price target to $14.70

Mackie Research Capital raised its price target for Medicure (TSX-V:MPH) to $14.70 from $6.90, reflecting the recent acquisition of a majority interest in Apicore as well as a change in the trend of Aggrastat...

February 17, 2017

Markets

Ladenburg starts Albireo Pharma at buy

Ladenburg Thalmann initiated coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $40 price target. The stock closed at $20.28 on Feb. 15. Albireo is focused on the development of novel bile acid modulators...

February 16, 2017

Markets

Roth resumes coverage of Lion Biotech at buy

Roth Capital Partners has reinitiated coverage of Lion Biotechnologies (NASDAQ:LBIO) with a “buy” rating and $14 price target. The stock closed at $7.15 on Feb. 14. Lion is developing autologous tumor infiltrating...

February 15, 2017

Markets

Maxim raises Ritter Pharma price target to $5

Maxim Group raised its price target for Ritter Pharmaceuticals (NASDAQ:RTTR) to $5 from $4 ahead of top-line data in the current quarter for a Phase 2b/3 study of RP-G28 for the treatment of lactose intolerance. The...

February 14, 2017

Category - Markets

Subscribe